ACAD
37.43
-0.2
-0.53%
AEMD
1.815
+0.06
+3.4076%
APRI
1.66
+0.005
+0.2840%
ARNA
24.83
-0.28
-1.12%
ATEC
2.2
+0.07
+3.29%
CNAT
5.32
-0.21
-3.80%
CRXM
0.151
0.00
0.00%
CYTX
0.373
-0.037
-9.0576%
DXCM
69.38
-0.12
-0.17%
GNMK
9.47
-0.09
-0.94%
HALO
16.595
-0.005
-0.030%
ILMN
200.51
+0.27
+0.13%
INNV
0.099
-0.001
-1.4014%
INO
6.17
-0.12
-1.91%
ISCO
1.95
+0.15
+8.33%
ISIS
57.56
0.00
0.00%
LGND
135.18
-0.63
-0.46%
LPTN
2.93
-2.93
-100.00%
MBVX
0.64
-0.1
-13.5270%
MEIP
2.74
0.00
0.00%
MNOV
6.073
+0.193
+3.2857%
MRTX
9.85
-0.5
-4.83%
MSTX
0.13
-0.01
-5.28%
NBIX
58.76
-0.07
-0.12%
NUVA
54.23
-0.38
-0.70%
ONCS
0.96
-0.02
-2.0410%
ONVO
2.01
0.00
0.00%
OREX
2.287
+0.002
+0.0744%
OTIC
3.25
-0.2
-5.80%
QDEL
43.04
-0.09
-0.21%
RCPT
231.96
0.00
0.00%
RGLS
1.29
-0.03
-2.27%
RMD
77.36
+0.04
+0.05%
SCIE
0
0.00
0.00%
SPHS
2.2
-0.04
-1.79%
SRNE
1.775
-0.025
-1.389%
TROV
0.691
+0.011
+1.5586%
VICL
2.41
0.00
0.00%
VOLC
18
0.00
0.00%
ZGNX
13.85
+0.8
+6.13%
ACAD
37.43
-0.2
-0.53%
AEMD
1.815
+0.06
+3.4076%
APRI
1.66
+0.005
+0.2840%
ARNA
24.83
-0.28
-1.12%
ATEC
2.2
+0.07
+3.29%
CNAT
5.32
-0.21
-3.80%
CRXM
0.151
0.00
0.00%
CYTX
0.373
-0.037
-9.0576%
DXCM
69.38
-0.12
-0.17%
GNMK
9.47
-0.09
-0.94%
HALO
16.595
-0.005
-0.030%
ILMN
200.51
+0.27
+0.13%
INNV
0.099
-0.001
-1.4014%
INO
6.17
-0.12
-1.91%
ISCO
1.95
+0.15
+8.33%
ISIS
57.56
0.00
0.00%
LGND
135.18
-0.63
-0.46%
LPTN
2.93
-2.93
-100.00%
MBVX
0.64
-0.1
-13.5270%
MEIP
2.74
0.00
0.00%
MNOV
6.073
+0.193
+3.2857%
MRTX
9.85
-0.5
-4.83%
MSTX
0.13
-0.01
-5.28%
NBIX
58.76
-0.07
-0.12%
NUVA
54.23
-0.38
-0.70%
ONCS
0.96
-0.02
-2.0410%
ONVO
2.01
0.00
0.00%
OREX
2.287
+0.002
+0.0744%
OTIC
3.25
-0.2
-5.80%
QDEL
43.04
-0.09
-0.21%
RCPT
231.96
0.00
0.00%
RGLS
1.29
-0.03
-2.27%
RMD
77.36
+0.04
+0.05%
SCIE
0
0.00
0.00%
SPHS
2.2
-0.04
-1.79%
SRNE
1.775
-0.025
-1.389%
TROV
0.691
+0.011
+1.5586%
VICL
2.41
0.00
0.00%
VOLC
18
0.00
0.00%
ZGNX
13.85
+0.8
+6.13%
Home » Archive by Category

Xconomy

Biogen Sets $750,000 Initial Price For First-Ever Spinal Atrophy Drug

December 28, 2016 – 10:46 am

[Updated, 12/29/16, see below] Patients with spinal muscular atrophy got some good news last week when the FDA approved nusinersen (Spinraza), making it the first marketed drug ever for the rare and…

[[Click headline to continue reading.]]

Ionis, Biogen Make History With FDA Nod for Spine Disease Drug

December 23, 2016 – 4:26 pm

Patients with spinal muscular atrophy got an early Christmas present on Friday. The FDA approved nusinersen (Spinraza), making the drug the first-ever marketed treatment for the rare, potentially…

[[Click headline to continue reading.]]

Bio Roundup: Crazy ’16, Trials of ’17, Senate on Drugs & More

December 23, 2016 – 5:00 am

You’ve probably seen the Internet memes. “When 2016 started, I looked like this. [Insert picture of young Leo DiCaprio.] Now I look like this. [Leo, with mountain beard, after…

[[Click headline to continue reading.]]

14 for ’17: Key Clinical Data To Watch For Next Year (Part 2)

December 22, 2016 – 4:45 am

We continue our look ahead to some of the clinical data due in 2017 that could shape healthcare practice and sway investor sentiment for years to come. Part one of our preview is here, with looks at…

[[Click headline to continue reading.]]

14 For ’17: Key Clinical Data to Watch For Next Year (Part 1)

December 21, 2016 – 12:10 pm

[Updated, 4:28 pm ET, see below] After years of research, frustration, hype, and millions (sometimes hundreds of millions) of dollars invested, a drug program boils down to the clinical…

[[Click headline to continue reading.]]

Acadia Drug Shows Early Promise in Treating Alzheimer’s Psychosis

December 20, 2016 – 10:22 am

An Acadia Pharmaceuticals drug developed to treat hallucinations and delusions experienced by Parkinson’s disease patients is now showing signs it could also treat similar psychoses associated with…

[[Click headline to continue reading.]]

Bio Roundup: NY Rises, Prez Inks Cures, Ophthotech Crashes & More

December 16, 2016 – 4:30 am

The 21st Century Cures Act is now law. New York wants to play in the biotech big leagues. The FDA under Trump will have license to approve drugs faster and could have a former top official back on…

[[Click headline to continue reading.]]

Organovo Discloses First Preclinical Data on Human Liver “Patch”

December 13, 2016 – 6:05 am

After taking the first steps toward the development of living human liver tissue “patches” for therapeutic use, San Diego-based Organovo (NASDAQ: ONVO) is laying out its pre-clinical data for the…

[[Click headline to continue reading.]]

San Diego Startup Raises $2.3M to Advance Enzymatic DNA Synthesis

December 12, 2016 – 5:30 am

Molecular Assemblies, a San Diego startup developing a new enzymatic method for synthesizing DNA, said today it has raised $2.3 million in a seed financing round. The funding will be used to hire…

[[Click headline to continue reading.]]

Amyloid Hypothesis Lives On—Solanezumab, Too, Despite “Siren Song”

December 9, 2016 – 11:41 am

When Eli Lilly (NYSE: LLY) reported the day before Thanksgiving, that its Alzheimer’s treatment solanezumab failed to significantly improve the condition of people with a mild form of the…

[[Click headline to continue reading.]]